NovaBay prices offering of shares and warrants

Tweet NovaBay Pharmaceuticals (AMEX:NBY) has priced an underwritten public offering of 5.9 million shares at a price of $1.25 a share, and one-year warrants to purchase up to 4,425,000 additional common shares. Net proceeds are expected to be about $6.34-million, excluding the exercise of any warrants. If the warrants are exercised in full, NovaBay would [...]

NovaBay receives equity funding from Pioneer Pharma

Tweet NovaBay Pharmaceuticals (AMEX:NBY) has received a $1.5-million equity investment from Pioneer Pharma (Singapore), an affiliate of Naqu Area Pioneer Pharma, a Shanghai-based company that markets high-end pharmaceutical products into China. As part of the expansion of the NeutroPhase distribution agreement for Southeast Asia announced in September, Pioneer has completed its investment of $2.5-million in [...]

NovaBay expands NeutroPhase deal in Southeast Asia

Tweet NovaBay Pharmaceuticals (AMEX:NBY) has expanded its commercial partnership agreement with Naqu Area Pioneer Pharma of Shanghai for the commercialization of NeutroPhase skin and wound cleanser in select Asian markets, in addition to China. Under the accord, NovaBay will receive an upfront payment of $500,000, with additional payments totaling $200,000 that may be triggered by [...]

New therapeutic technique for necrotizing fasciitis

Tweet NovaBay Pharmaceuticals (AMEX:NBY) said a case study of a new therapeutic technique for the management of necrotizing fasciitis, using its NeutroPhase skin and wound cleanser in combination with negative pressure wound therapy, was presented at the 2012 Fall Symposium on Advanced Wound Care in Baltimore. “The successful outcome of this particular patient case is [...]

NovaBay co-authors study on bacterial toxins

Tweet NovaBay Pharmaceuticals (AMEX:NBY) said data supporting the mechanism of action for its lead Aganocide compound, NVC-422, against toxins secreted by bacteria such as Escherichia coli (E. coli) were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco in a poster that featured a collaborative study with the Innsbruck Medical University. [...]

BioMedReports discusses NovaBay pipeline-catalysts

Tweet BioMedReports has published a new detailed report on NovaBay Pharmaceuticals (AMEX:NBY) that highlights its two distinct anti-infective product lines: NVC-422 and NeutroPhase. Both compounds are designed to work by mimicking the body’s natural defense against infection. Among other things in the article, biotech columnist Scott Matusow writes that a market capitalization of $120-million to [...]

NovaBay gets additional FDA clearance for NeutroPhase

Tweet NovaBay Pharmaceuticals (AMEX:NBY) has received 510(k) clearance from the FDA to market its NeutroPhase skin and wound cleanser under widened indications, including the moistening and debriding of graft and donor sites. The FDA also cleared NeutroPhase to be administered through a new convenient spray pump. NovaBay is currently seeking appropriate potential partners to out-license [...]

NovaBay’s NeutroPhase cleans up flesh-eating disease

Tweet Last January, Lori Madsen fell in the parking lot at work in Pacifica, Calif., just outside San Francisco, scrapping the skin of her elbow. Within several days, she was rushed to hospital, with swelling in her arm, intense pain and fever. As well, her blood pressure was dropping as she was going into septic [...]

NovaBay partner readies impetigo trial

Tweet After completing an end-of-Phase 2a meeting with the FDA, NovaBay Pharmaceuticals (AMEX:NBY) expects its partner, Galderma S.A., to begin a global Phase 2b clinical trial with NVC-422 for treating impetigo by the end of the third quarter this year. In the second quarter report, CEO Dr. Ron Najafi said NovaBay made “significant progress” across [...]

NovaBay aganocides featured in EyeWorld

Tweet In an article in the May issue of EyeWorld, the newsmagazine of the American Society of Cataract and Refractive Surgery, NovaBay Pharmaceuticals (NYSE AMEX:NBY) CEO Dr. Ron Najafi and other members of his ophthalmology team discuss the ability of the company’s topical aganocide compounds to kill bacteria, viruses and fungi without developing drug resistance. Aganocides [...]

Next Page »